Výsledky vyhledávání

Quality of life in patients aged 65 years and older with overactive bladder treated with mirabegron across eight European countries: Secondary analysis of BELIEVE

Autor: Jameel Nazir, Anny Stari, Moses Huang, Nurul Choudhury, Robert Freeman, Stephen Foley

Publikováno v: International journal of urology : official journal of the Japanese Urological AssociationReferences. 26(9)

OBJECTIVES To describe quality of life outcomes in patients with overactive bladder aged ≥65 years receiving mirabegron, a β3-adrenoreceptor agonist (BELIEVE). METHODS BELIEVE was a European, prospective, non-interventional, real-world study of 84

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5c9e44e4774c045dcc781e5dfd5e269d
https://pubmed.ncbi.nlm.nih.gov/31847049

Zobrazit plný text záznamu

Mirabegron improves quality-of-life, treatment satisfaction, and persistence in patients with overactive bladder: a multi-center, non-interventional, real-world, 12-month study

Autor: Steve Foley, Moses Huang, Robert Freeman, Robert Grill, Anny Stari, Nurul Choudhury, Zuzana Kachlirova, José Rosa Arias, E. Vicente

Publikováno v: Current medical research and opinion. 34(5)

Observational studies can provide evidence about patient outcomes in routine clinical practice. This prospective, non-interventional study (BELIEVE) is the largest real-world European study to date to assess quality-of-life, treatment satisfaction, r

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::17bbfb649ed5875ce7ba438d628a4c84
https://pubmed.ncbi.nlm.nih.gov/29254376

Zobrazit plný text záznamu

Clinical Outcomes and Testosterone Levels Following Continuous Androgen Deprivation in Patients with Relapsing or Locally Advanced Prostate Cancer: A Post Hoc Analysis of the ICELAND Study

Autor: Bertrand Tombal, Anny Stari, Francisco Gómez Veiga, Raj Persad, Erik B. Cornel, Claude Schulman

Publikováno v: The Journal of urology. 198(5)

Lower serum testosterone levels correlate with improved cause specific survival and longer time to progression in year 1 of continuous androgen deprivation in men with prostate cancer. ICELAND was a large European study demonstrating the efficacy of

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::af5f2712dbcba47a89a709090870ce97
https://pubmed.ncbi.nlm.nih.gov/28552710

Zobrazit plný text záznamu

Clinical outcomes and testosterone levels following continuous androgen deprivation (CAD) in patients with relapsing or locally advanced prostate cancer (PC): A post hoc analysis of the ICELAND study

Autor: Claude Schulman, W. Warnack, Anny Stari, Raj Persad, Teuvo L.J. Tammela, F.G. Veiga, Vsevolod Matveev, J. Schraml, Bertrand Tombal, E. Cornel

Publikováno v: Annals of Oncology. 27:vi252

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::fcad60541d660bbb3e8bef7cac7bae2d
https://doi.org/10.1093/annonc/mdw372.26

Zobrazit plný text záznamu

The PRESIDE trial: A randomized, double-blind, placebo-controlled phase III efficacy and safety study of continued enzalutamide plus docetaxel after disease progression on enzalutamide alone in patients with metastatic castration-resistant prostate cancer

Autor: Alex Coppell, Richard Davidson, Hossein Mobasheri, Anny Stari, Simon Chowdhury, Cecil Treadwell, Axel S. Merseburger, Robert Snijder

Publikováno v: Journal of Clinical Oncology. 33:TPS5083-TPS5083

TPS5083 Background: Enzalutamide (ENZA) is an oral androgen receptor inhibitor approved in the US for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) (US PI, ...

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::af7df427c91cbeb574dc041def6b57d4
https://doi.org/10.1200/jco.2015.33.15_suppl.tps5083

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání